X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-01-15 | CADL | Barone Francesca | Chief Scientific Officer | S - Sale | $7.23 | -13,534 | 110,673 | -11% | -$97,783 | ||||||
2025-01-15 | CADL | Tyagarajan Seshu | CTO | S - Sale | $7.23 | -14,322 | 96,790 | -13% | -$103,476 | ||||||
2025-01-15 | CADL | Schoch Charles | See Remarks | S - Sale | $7.23 | -9,511 | 43,038 | -18% | -$68,717 | ||||||
2025-01-15 | CADL | Tak Paul Peter | CEO | S - Sale | $7.23 | -21,704 | 251,912 | -8% | -$156,811 | ||||||
2025-01-15 | CADL | Nichols William Garrett | Chief Medical Officer | S - Sale | $7.23 | -10,428 | 79,320 | -12% | -$75,342 | ||||||
2025-01-08 | CADL | Barone Francesca | Chief Scientific Officer | S - Sale | $8.22 | -13,673 | 124,207 | -10% | -$112,367 | ||||||
2025-01-08 | CADL | Schoch Charles | See Remarks | S - Sale | $8.22 | -9,971 | 52,549 | -16% | -$81,944 | ||||||
2025-01-08 | CADL | Tak Paul Peter | CEO | S - Sale | $8.22 | -21,172 | 273,616 | -7% | -$173,996 | ||||||
2025-01-08 | CADL | Tyagarajan Seshu | CTO | S - Sale | $8.22 | -14,545 | 111,112 | -12% | -$119,534 | ||||||
2025-01-08 | CADL | Nichols William Garrett | Chief Medical Officer | S - Sale | $8.22 | -10,799 | 89,748 | -11% | -$88,749 | ||||||
2024-12-16 | CADL | Manning Paul B | Dir | P - Purchase | $6.00 | +1,250,000 | 4,127,158 | +43% | +$7,500,000 | ||||||
2024-11-29 | CADL | Tyagarajan Seshu | CTO | S - Sale | $4.56 | -20,392 | 125,657 | -14% | -$92,898 | ||||||
2024-11-29 | CADL | Tak Paul Peter | CEO | S - Sale | $4.56 | -48,847 | 294,788 | -14% | -$222,527 | ||||||
2024-11-29 | CADL | Nichols William Garrett | Chief Medical Officer | S - Sale | $4.56 | -13,935 | 100,547 | -12% | -$63,482 | ||||||
2024-11-29 | CADL | Barone Francesca | Chief Scientific Officer | S - Sale | $4.56 | -22,081 | 137,880 | -14% | -$100,592 | ||||||
| M | 2024-10-11 | CADL | Aguilar-Cordova Estuardo | 10% | S - Sale | $6.03 | -40,412 | 6,053,781 | -1% | -$243,834 | |||||
| M | 2024-10-01 | CADL | Aguilar-Cordova Estuardo | 10% | S - Sale | $6.93 | -35,002 | 6,094,193 | -1% | -$242,642 | |||||
2024-07-17 | CADL | Tyagarajan Seshu | CTO | S - Sale | $6.47 | -14,851 | 146,049 | -9% | -$96,125 | ||||||
2024-07-17 | CADL | Tak Paul Peter | CEO | S - Sale | $6.47 | -22,528 | 330,735 | -6% | -$145,815 | ||||||
2024-07-17 | CADL | Schoch Charles | See Remarks | S - Sale | $6.47 | -9,884 | 62,520 | -14% | -$63,975 | ||||||
2024-07-17 | CADL | Nichols William Garrett | Chief Medical Officer | S - Sale | $6.47 | -10,875 | 114,482 | -9% | -$70,390 | ||||||
2024-07-17 | CADL | Barone Francesca | Chief Scientific Officer | S - Sale | $6.47 | -14,051 | 159,961 | -8% | -$90,947 | ||||||
2024-07-11 | CADL | Tyagarajan Seshu | CTO | S - Sale | $5.97 | -13,330 | 160,900 | -8% | -$79,625 | ||||||
2024-07-11 | CADL | Tak Paul Peter | CEO | S - Sale | $5.97 | -20,293 | 353,263 | -5% | -$121,218 | ||||||
2024-07-11 | CADL | Schoch Charles | See Remarks | S - Sale | $5.97 | -8,897 | 72,404 | -11% | -$53,145 | ||||||
2024-07-11 | CADL | Nichols William Garrett | Chief Medical Officer | S - Sale | $5.97 | -9,769 | 125,357 | -7% | -$58,354 | ||||||
2024-07-11 | CADL | Barone Francesca | Chief Scientific Officer | S - Sale | $5.97 | -12,645 | 174,012 | -7% | -$75,534 | ||||||
| AM | 2022-12-08 | CADL | Martell Christopher | Dir | P - Purchase | $1.89 | +27,000 | 435,514 | +7% | +$51,108 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |